Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for L
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<